Jasper

Jasper Therapeutics is focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. In 2025, Jasper reported Phase 1/2 data from the BEACON study of briquilimab in chronic spontaneous urticaria (CSU). Jasper was founded out of Stanford and JSP-191 was invented and developed at Amgen. The company recently announced a merger with Kira Pharmaceuticals with a lead program comprising an Anti-C5 mAb + Factor H Bifunctional biologic for PNH moving into registrational trials.